GlassScriptPhysician profile
Peter Dominick
NPI 1639644198
$10,173.94
in general payments reported to CMS, 2019-2025
24 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,271 · 2022: $2,153 · 2023: $2,516 · 2024: $2,205 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,375 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,375.32 |
| Education | $375.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,067.34 | 2021-2025 | |
| Genzyme Corporation | $1,348.19 | 2021-2025 | |
| Janssen Biotech, INC. | $995.63 | 2021-2025 | Tremfya |
| Pfizer INC. | $715.03 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $663.93 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $624.79 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $608.63 | 2021-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $571.73 | 2022-2025 | Sotyktu |
| Ucb, INC. | $539.82 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $496.99 | 2021-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $495.82 | 2021-2025 | |
| Hill Dermaceuticals, INC. | $313.72 | 2021-2025 | Tolak |
| Incyte Corporation | $167.48 | 2022-2024 | Opzelura |
| Amgen INC. | $163.31 | 2022-2024 | Otezla |
| Organon LLC | $101.33 | 2024-2025 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $82.02 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $58.96 | 2023 | |
| Galderma Laboratories, L.P. | $54.54 | 2024-2025 | Nemluvio |
| Janssen Pharmaceuticals, INC | $26.34 | 2025 | Tremfya |
| Journey Medical Corporation | $18.96 | 2022 | |
| Organogenesis INC. | $16.12 | 2024 | Puraply Am |
| Verrica Pharmaceuticals INC. | $15.59 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $14.31 | 2021 | |
| Almirall LLC | $13.36 | 2023 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dominick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.